Abstract
Thymic neoplasms are rare malignant tumors, and the mainstay of treatment for patients with thymic tumors is surgical resection. Chemotherapy is necessary for patients with extensive tumor invasion or metastasis who are unable to undergo complete radical excision. However, only two-thirds of these patients respond to chemotherapy. For those patients who are resistant to chemotherapy, targeted therapy has been proposed as a beneficial alternative. Many genes implicated in tumorigenesis and metastasis have been demonstrated to be therapeutic targets in thymic malignancies. Currently, a number of case reports and small clinical trials have reported that a few inhibitors, such as sorafenib and sunitinib, are effective for the treatment of thymoma. This review describes the current potential drug targets and their roles in the development of thymic malignancy. Drugs that are used for the targeted therapy of thymoma and the results of related clinical trials are addressed. Furthermore, we provide an overview of the screening of specific patients who are suitable for targeted therapy and the efficacy of targeted therapy in patients with refractory or recurrent thymic tumors.
Keywords: Cancer therapy, carcinogenesis, targeted therapy, thymic neoplasms, thymic carcinoma, thymoma.
Current Cancer Drug Targets
Title:Current Drug Targets for Thymic Neoplasms
Volume: 15 Issue: 7
Author(s): Xiao-Ling Xu and Wei-Min Mao
Affiliation:
Keywords: Cancer therapy, carcinogenesis, targeted therapy, thymic neoplasms, thymic carcinoma, thymoma.
Abstract: Thymic neoplasms are rare malignant tumors, and the mainstay of treatment for patients with thymic tumors is surgical resection. Chemotherapy is necessary for patients with extensive tumor invasion or metastasis who are unable to undergo complete radical excision. However, only two-thirds of these patients respond to chemotherapy. For those patients who are resistant to chemotherapy, targeted therapy has been proposed as a beneficial alternative. Many genes implicated in tumorigenesis and metastasis have been demonstrated to be therapeutic targets in thymic malignancies. Currently, a number of case reports and small clinical trials have reported that a few inhibitors, such as sorafenib and sunitinib, are effective for the treatment of thymoma. This review describes the current potential drug targets and their roles in the development of thymic malignancy. Drugs that are used for the targeted therapy of thymoma and the results of related clinical trials are addressed. Furthermore, we provide an overview of the screening of specific patients who are suitable for targeted therapy and the efficacy of targeted therapy in patients with refractory or recurrent thymic tumors.
Export Options
About this article
Cite this article as:
Xu Xiao-Ling and Mao Wei-Min, Current Drug Targets for Thymic Neoplasms, Current Cancer Drug Targets 2015; 15 (7) . https://dx.doi.org/10.2174/1568009615666150616124155
DOI https://dx.doi.org/10.2174/1568009615666150616124155 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Managing Skin Malignancies- How Family Doctors, Plastic Surgeons, and Dermatologists Can Help
Current Cancer Therapy Reviews PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
Current Pharmaceutical Design Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry Exploring Confluence-Related Signalling to Modulate the Expression of Oct4 – A Role in Facilitating Mouse Somatic Cell Reprogramming?
Current Stem Cell Research & Therapy The miRNAs and Epithelial-Mesenchymal Transition in Cancers
Current Pharmaceutical Design Prodrugs in Photodynamic Anticancer Therapy
Current Pharmaceutical Design A Review of the Three-Dimensional Cell Culture Technique: Approaches, Advantages and Applications
Current Stem Cell Research & Therapy Targeted Pathways in Breast Cancer: Molecular and Protein Markers Guiding Therapeutic Decisions
Current Molecular Pharmacology Searching for Novel Cancer Chemopreventive Plants and their Products:The Genus Zanthoxylum
Current Drug Targets MicroRNAs in Breast Cancer Therapy
Current Pharmaceutical Design Wnt Signaling and Cell-Matrix Adhesion
Current Molecular Medicine The Leukocyte Common Antigen-Related Protein LAR: Candidate PTP for Inhibitory Targeting
Current Topics in Medicinal Chemistry Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems
Current Neuropharmacology Apoptotic Effects of Bilirubin on Skin Cancer Cell Lines SK-MEL-3 (Melanoma) and A431 (Non-Melanoma)
Anti-Cancer Agents in Medicinal Chemistry Role of P-Glycoprotein in the Intestinal Absorption of Tanshinone IIA, a Major Active Ingredient in the Root of Salvia miltiorrhiza Bunge
Current Drug Metabolism Applications and Limitations of Genetically Modified Mouse Models in Drug Discovery and Development
Current Drug Metabolism Proteomics in the Search for Biomarkers of Animal Cancer
Current Protein & Peptide Science